8 Continuous vs 8 Intermittent Cycles in First and Second Line Treatment of Patients With HER2/Neu Negative, Incurable, Metastatic or Unresectable Locally Advanced Breast Cancer.

Trial Profile

8 Continuous vs 8 Intermittent Cycles in First and Second Line Treatment of Patients With HER2/Neu Negative, Incurable, Metastatic or Unresectable Locally Advanced Breast Cancer.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Nov 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Paclitaxel (Primary) ; Capecitabine; Doxorubicin liposomal
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms Stop and Go
  • Most Recent Events

    • 12 Sep 2017 Safety results will be presented at the meeting as per results presented at the 42nd European Society for Medical Oncology Congress
    • 12 Sep 2017 Primary endpoint has not been met. (Progression free survival) as per results presented at the 42nd European Society for Medical Oncology Congress
    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top